Search alternatives:
significant gender » significant concern (Expand Search), significant burden (Expand Search)
gender decrease » greater decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significant gender » significant concern (Expand Search), significant burden (Expand Search)
gender decrease » greater decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
201
-
202
-
203
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
204
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
205
-
206
-
207
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
208
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
209
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
210
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
211
-
212
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
213
-
214
-
215
-
216
-
217
-
218
-
219
B2 decreases glycolytic intermediates in cells.
Published 2025“…Other abbreviations: HGA, DL-hydroxyglutaric acid; PEP, phosphoenolpyruvic acid; 3-PGA, 3-phosphoglyceric acid; G3P; glyceraldehyde 3-phosphate; Data (n = 5) are shown as mean±SD. Not significant (ns): **<i>P</i> ≤ 0.01, ****<i>P</i> ≤ 0.0001by one-way ANOVA with multiple comparison of the mean of each test group to the mean of the vehicle control. …”
-
220